Epigenomic Control of KSHV Latency

KSHV 潜伏期的表观基因组控制

• 批准号: 10304175
• 负责人: PAUL M LIEBERMAN
• 金额: $ 35.38万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10304175
• 关键词: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Angiolymphoid hyperplasia; Architecture; Attenuated; Autoimmune Diseases; B-Lymphocytes; BRD2 gene; Binding; Bromodomain; Chromatin; Chromatin Structure; Chromosome Structures; Chromosomes, Human, 4-5; Complex; Complex Mixtures; Crystallization; DAXX gene; DNA Binding; DNA Binding Domain; Data; Disease; EZH2 gene; Endothelial Cells; Epigenetic Process; Episome; Etiology; Gene Expression; Genetic Transcription; Genome; HIV; Herpesviridae; Herpesviridae Infections; Heterochromatin; Human Herpesvirus 8; Immediate-Early Genes; Infection; Kaposi Sarcoma; Knowledge; Lesion; Link; Lupus Erythematosus; Lymphoid; Lymphoma; Lymphoproliferative Disorders; Lytic; Maintenance; Malignant Neoplasms; Mediating; Molecular; Molecular Conformation; Multicentric Angiofollicular Lymphoid Hyperplasia; Multiple Sclerosis; Mutation; Pathogenesis; Pathway interactions; Patients; Pharmacology; Pleural effusion disorder; Polycomb; Process; Protein Family; Proteins; Roentgen Rays; Role; Structure; System; Therapeutic Intervention; Transcript; Transcriptional Regulation; Viral; Viral Genes; Viral Pathogenesis; Virus Diseases; biological adaptation to stress; cellular imaging; chronic infection; cohesin; driving force; endoplasmic reticulum stress; epigenome; epigenomics; imaging study; inhibitor; latent infection; lytic gene expression; male; mutant; neoplastic cell; novel; protein function; response; sensor; small molecule inhibitor; transcriptomics; tumorigenesis

KSHV is the causative agent of all forms of Kaposi’s sarcoma (KS). KS is the most common form of cancer in males in sub-Saharan Africa and HIV-AIDS patients. KSHV is also responsible for several lymphoid disorders, including pleural effusion lymphoma (PEL) and Castleman’s disease. Long-term latent infection in B- lymphocytes and persistent infection in endothelial cells is thought to be a major driving force for KSHV oncogenesis. KSHV pathogenesis depends on viral persistence and highly regulated gene expression during latent infection. We have focused on epigenetic and chromatin organizing factors that regulate viral gene expression and maintain stable latency in KSHV infected tumor cells. Here, we expand our studies on the X- ray crystal structures of KSHV encoded LANA to explore its propensity to form higher-order oligomeric complexes that are necessary for episome maintenance. We investigate the relationship between LANA oligomerization and chromatin organization mediated by cellular factors, including the chromatin organizing factors CTCF and cohesins and the heterochromatin regulatory factors DAXX and EZH2. We also investigate how the bromodomain proteins BRD2 and BRD4 bind to the basic patch of the LANA DNA binding domain, and how these BET-proteins function to facilitate LANA chromatin binding, and epigenome architecture. We discovered that small molecule inhibitors of BET proteins, like JQ1, are potent activators of KSHV lytic gene expression, and investigate how disruption of BRD2 or BRD4 function alters the KSHV epigenome. Finally, we analyze transcriptomic data from KS lesions to reveal a central role of the Unfolded Protein Response (UPR) in regulating KSHV latency. We find that inducers of the UPR disrupt KSHV latency through a mechanism involving the rapid proteolytic cleavage of the Cohesin subunit RAD21. We propose that RAD21 cleavage functions as a rapid release trigger for lytic reactivation, and therefore represents a novel chromatin- conformation sensor mechanism for UPR stress. The potential mechanistic relationship between UPR and the RAD21-BRD2/4-LANA axis will be investigated. Finally, we explore how pharmacological inhibition of UPR may modulate KSHV gene expression to ameliorate KS progression and pathogenesis. These studies will advance our knowledge of KSHV infection opportunities for therapeutic intervention in KSHV-associated disease.

KSHV是所有形式卡波西肉瘤（KS）的病原体。KS是撒哈拉以南非洲男性和艾滋病毒/艾滋病患者中最常见的癌症形式。KSHV还引起几种淋巴系统疾病，包括胸腔积液淋巴瘤（PEL）和Castleman病。B淋巴细胞的长期潜伏感染和内皮细胞的持续感染被认为是KSHV肿瘤发生的主要驱动力。KSHV的致病机制依赖于潜伏感染过程中病毒的持续存在和高度调控的基因表达。我们一直专注于表观遗传和染色质组织因子，调节病毒基因表达，并保持稳定的潜伏期KSHV感染的肿瘤细胞。在这里，我们扩展了我们对KSHV编码的拉娜的X射线晶体结构的研究，以探索其形成附加体维持所必需的高阶寡聚复合物的倾向。我们研究了拉娜寡聚化和细胞因子介导的染色质组织之间的关系，包括染色质组织因子CTCF和粘附素以及异染色质调节因子DAXX和EZH 2。我们还研究了布罗莫结构域蛋白BRD 2和BRD 4如何与拉娜DNA结合结构域的基本补丁结合，以及这些BET蛋白如何起作用以促进拉娜染色质结合和表观基因组结构。我们发现BET蛋白的小分子抑制剂，如JQ 1，是KSHV裂解基因表达的有效激活剂，并研究了BRD 2或BRD 4功能的破坏如何改变KSHV表观基因组。最后，我们分析了KS病变的转录组数据，揭示了未折叠蛋白反应（UPR）在调节KSHV潜伏期中的核心作用。我们发现，诱导剂的UPR破坏KSHV的潜伏期，通过一种机制，涉及快速蛋白水解切割的粘附素亚基RAD 21。我们提出，RAD 21裂解功能作为一个快速释放触发裂解再激活，因此代表了一种新的染色质构象传感器机制的UPR应力。研究了UPR与RAD 21-BRD 2/4-拉娜轴之间的潜在机理关系。最后，我们探讨了药物抑制UPR如何调节KSHV基因表达，以改善KS进展和发病机制。这些研究将提高我们对KSHV感染的认识，为KSHV相关疾病的治疗干预提供机会。